A Double Blind, Randomized, Repeat Dose Parallel Group Study of Recombinant Human Parathyroid Hormone Analog Tablets, or Placebo Tablets, Compared to Open Label Forsteo in Postmenopausal Women With Osteoporosis

Trial Profile

A Double Blind, Randomized, Repeat Dose Parallel Group Study of Recombinant Human Parathyroid Hormone Analog Tablets, or Placebo Tablets, Compared to Open Label Forsteo in Postmenopausal Women With Osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Parathyroid hormone (Primary) ; Teriparatide
  • Indications Postmenopausal osteoporosis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Unigene Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Mar 2013 This study was the subject of an oral presentation at the 2012 Annual Meeting of the American Society of Bone and Mineral Research (ASBMR), according to a Unigene Laboratories media release.
    • 01 Mar 2013 Results published in Bone.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top